EL PASO, TX, United States, via ETELIGIS INC., 06/04/2015 – – Premier Biomedical, Inc. (OTCQB: BIEI), announced that their sponsored partner in R&D, the University of Texas at El Paso (UTEP) (http://www.utep.edu/), has developed a unique antibody against three immune suppressors, CTLA-4, PD1, and BTLA. A Provisional Patent Application on this antibody family was filed early in May. Premier Biomedical is planning to initiate an application for achieving approval by the Food and Drug Administration (FDA) for utilization of the compound as a major cancer immunotherapy drug. Immunotherapy, seeks to harnesses the power of the immune system in order to attack cancer.
Premier Biomedical’s Vice President of Scientific Development, David Vigerust, Ph.D. stated that, “We are very excited about this enormous achievement developed in conjunction with our UTEP team. The initial data has shown superior adhesion to CTLA-4 in tests conducted to date. Better adhesion could result in better blocking of CTLA-4, making it easier for the immune system to attack cancer. We believe that this could potentially exceed the performance of the existing commercially available anti-cancer drugs on the market. An accelerated test and development program has been launched as a result of these promising results.”
William A. Hartman, President and CEO of Premier Biomedical, stated, “This development puts us on the leading edge of cancer research in an industry niche that has been estimated at up to $40 Billion. We intend to do everything in our power to complete laboratory experimentation and move toward human testing as rapidly as possible to eliminate a variety of cancer types.”
Dr. Georgialina Rodriguez of UTEP, a lead researcher on the project stated, “We are very interested in learning more about how these immune therapies, or cancer checkpoint inhibitors, work to fight off cancer, including drugs that target molecules like CTLA4 on T-cells. There is recent data showing that targeting two, and possibly more, of these proteins can have even greater cancer therapeutic effects which makes this research very exciting.”
About University of Texas at El Paso
The University of Texas at El Paso (UTEP) is part of the University of Texas System consisting of nine universities and six health institutions. UTEP is accredited by the Southern Association of Colleges and Schools (SACS) (http://www.sacs.org/). UTEP is staffed by some of the nation’s leading research scientists, and is ranked as one of the Top Ten Research Universities in the U.S. by Washington Monthly magazine. UTEP was established in 1914 and is currently celebrating its centennial of distinguished service to the El Paso region.
About Premier Biomedical, Inc.
Premier Biomedical, Inc. is a research-based company that intends to discover and develop medical treatments for a wide range of diseases in humans. Premier has licensed the technology behind multiple provisional patents in the United States and a PCT Europe National Patent in the areas of Cancer, Sepsis, and Multiple Sclerosis. Founded in 2010, Premier has partnered with the Department of Defense with Center of Expertise at the William Beaumont Army Medical Center and the University of Texas at El Paso (UTEP). The company’s R&D efforts are centered in El Paso, TX and their business offices are in Western Pennsylvania. The Company’s common stock trades on the fully reporting Over-The-Counter Bulletin Board under the ticker symbol "BIEI." http://www.premierbiomedicalinc.com/
Safe Harbor Notice
Certain statements contained herein are “forward-looking statements” (as defined in the Private Securities Litigation Reform Act of 1995). Premier Biomedical, Inc. cautions that statements, and assumptions made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. These statements may address issues that involve significant risks, uncertainties, estimates made by management. Actual results could differ materially from current projections or implied results. Premier Biomedical, Inc. undertakes no obligation to revise these statements following the date of this news release.
Premier Biomedical, Inc.
SOURCE: Premier Biomedical, Inc.